Skip to main content
. 2023 Apr 11;7(14):3644–3650. doi: 10.1182/bloodadvances.2022009505

Figure 1.

Figure 1.

Cumulative incidence of all cGVHD and mild/moderate/severe cGVHD since day 120. Competing risks are death without cGVHD (A-D) and other severities of cGVHD (B-D).